← Leaderboards
Mohammad Azam
Cincinnati Childrens Hosp Med Ctr
$5,839,846
Attributed
$6,567,583
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $852.1K · FY2012–24$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,567,583 · 5
By mechanism
R01$5,757,297 · 3
R21$810,286 · 2
Top collaborators
- Daniel Starczynowski3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Daniel Starczynowski$17,551,895
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationResistanceMediatingResponseMouse ModelMolecularChronic Myeloid LeukemiaProtein Tyrosine KinasePhosphotransferasesRegulationInsightOverexpressionKinase InhibitorSignal TransductionIn VitroSmall MoleculeCellsGeneticCancer CellTyrosine Kinase InhibitorPharmaceutical PreparationsBiochemicalLeukemiaMedicine
Grant awards (19)
Mechanism of Therapy in high-risk AML$463,996
R01 · FY2024 · CA · contact PI
Target the Dusp1 in Jak2 dependent myeloproliferative neoplasm (MPN) for curative treatment$178,205
R21 · FY2024 · CA · contact PI
Mechanism of Therapy in high-risk AML$478,645
R01 · FY2023 · CA · contact PI
Target the Dusp1 in Jak2 dependent myeloproliferative neoplasm (MPN) for curative treatment$225,101
R21 · FY2023 · CA · contact PI
Mechanism of Therapy in high-risk AML$478,645
R01 · FY2022 · CA · contact PI
Mechanism of non-oncogene addiction$356,438
R01 · FY2022 · CA · contact PI
Mechanism of Therapy in high-risk AML$488,415
R01 · FY2021 · CA · contact PI
Mechanism of non-oncogene addiction$363,713
R01 · FY2021 · CA · contact PI
Mechanism of Therapy in high-risk AML$488,415
R01 · FY2020 · CA · contact PI
Mechanism of non-oncogene addiction$363,713
R01 · FY2020 · CA · contact PI
Mechanism of non-oncogene addiction$352,801
R01 · FY2019 · CA · contact PI
Mechanism of non-oncogene addiction$363,713
R01 · FY2018 · CA · contact PI
Improved therapeutic approaches for hematological disorder treated with tyrosine$317,475
R01 · FY2016 · CA · contact PI
Improved therapeutic approaches for hematological disorder treated with tyrosine$317,475
R01 · FY2015 · CA · contact PI
Improved therapeutic approaches for hematological disorder treated with tyrosine$307,951
R01 · FY2014 · CA · contact PI
Mechanisms of drug resistance in Myeloproliferative neoplasms treated with JAK2 i$224,910
R21 · FY2014 · HL · contact PI
Improved therapeutic approaches for hematological disorder treated with tyrosine$298,427
R01 · FY2013 · CA · contact PI
Mechanisms of drug resistance in Myeloproliferative neoplasms treated with JAK2 i$182,070
R21 · FY2013 · HL · contact PI
Improved therapeutic approaches for hematological disorder treated with tyrosine$317,475
R01 · FY2012 · CA · contact PI